Table 1.
Demographic characteristics
| C23 (Gallbladder) (n = 52,712) |
C24 (Extrahepatic bile duct) (n = 76,787) |
C25 (Pancreas) (n = 129,355) |
|
|---|---|---|---|
| Age group (yr) | |||
| 0–39 | 518 (1.0) | 518 (0.7) | 2,595 (2.0) |
| 40–49 | 2,318 (4.4) | 2,805 (3.7) | 7,406 (5.7) |
| 50–59 | 6,931 (13.2) | 9,723 (12.7) | 20,681 (16.0) |
| 60–69 | 13,929 (26.4) | 20,621 (26.9) | 36,074 (27.9) |
| 70–79 | 17,712 (33.6) | 26,373 (34.4) | 39,956 (30.9) |
| ≥ 80 | 11,304 (21.4) | 16,747 (21.8) | 22,643 (17.5) |
| Sex | |||
| Male | 22,859 (43.4) | 44,127 (57.5) | 69,413 (53.7) |
| Female | 29,853 (56.6) | 32,660 (42.5) | 59,942 (46.3) |
| First course of treatment | |||
| Surgical | 22,899 (43.4) | 35,106 (45.7) | 28,994 (22.4) |
| Non-surgical | 7,358 (14.0) | 6,400 (8.3) | 38,755 (30.0) |
| No active or unknown treatment | 22,455 (42.6) | 35,281 (46.0) | 61,606 (47.6) |
| SEER stage (2006–2022)a) | |||
| Localized | 7,691 (18.6) | 16,351 (26.0) | 13,060 (12.1) |
| Regional | 14,554 (35.2) | 27,030 (42.9) | 32,879 (30.5) |
| Distant | 14,657 (35.5) | 7,896 (12.5) | 45,921 (42.6) |
| Unstaged | 4,419 (10.7) | 11,744 (18.6) | 15,921 (14.8) |
Values are presented as number (%).
SEER, Surveillance, Epidemiology, and End Results.
a)Percentages indicate the relative distribution within the total number of cases by SEER stage classification.